GYRE Live signals | Maximize Profits with Getagraph.com

SELL 118655 min ago

@ $11.05

Issued: 14 Feb 2024 @ 09:30

Return: 34.12%

Previous signal: Feb 9 - 14:19

Previous signal: Buy

Return: -7.22 %

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 16:00):

Stats
Today's Volume	41 596.00
Average Volume	77 988.00
Market Cap	1.27B
EPS	$0 ( 2024-04-04 )
Next earnings date	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0470 (0.32%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Usman Nassim	Sell	20 000	Stock Option (Right to Buy)
2024-05-01	Usman Nassim	Buy	20 000	Common Stock
2024-05-01	Usman Nassim	Sell	14 900	Common Stock
2024-05-01	Usman Nassim	Sell	5 000	Common Stock
2024-05-01	Usman Nassim	Sell	100	Common Stock

INSIDER POWER
-32.00
Last 12 transactions
Buy: 61 866 \| Sell: 120 000

Volume Correlation

Long: -0.15 (neutral)

Short: -0.80 (strong negative)

Signal:(38.084) Neutral

Gyre Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gyre Therapeutics, Inc. Correlation - Currency/Commodity

0.10
( neutral )

-0.08
( neutral )

0.00
( neutral )

-0.11
( neutral )

0.01
( neutral )

Gyre Therapeutics, Inc. Financials

Annual	2023
Revenue:	$113.45M
Gross Profit:	$108.81M (95.91 %)
EPS:	$-1.410

FY	2023
Revenue:	$113.45M
Gross Profit:	$108.81M (95.91 %)
EPS:	$-1.410

Financial Reports:

No articles found.

Gyre Therapeutics, Inc.

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.